Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Vazyme Biotech

Request full access

Biotechnology reagents and materials for life sciences research

ChinaFounded 2012Biotech & Life Sciences

About Vazyme Biotech

Vazyme Biotech is a biotechnology company focused on the research, development, and production of functional proteins like enzymes, antigens, and antibodies. Founded in 2012 by Dr. Cao Lin, a former university professor, the company was born from the need for more accessible and affordable research reagents. Dr. Cao, who holds a Ph.D. from Nanjing University and an EMBA from China Europe International Business School, established Vazyme with a group of like-minded colleagues to develop enzyme-based solutions for technical challenges in the field.

The company operates across several business sectors, including life sciences, in vitro diagnostics (IVD), and biopharmaceuticals. Its business model involves the in-house production and sale of core raw materials and finished products. Revenue streams are primarily generated from product sales, such as reagents and kits for research and clinical diagnostics, and to a lesser extent, from contract research services. Vazyme serves a global clientele that includes over 10,000 business customers, such as biopharmaceutical companies, research institutions, and hospitals across more than 60 countries. A significant milestone was achieved on November 15, 2021, when the company was listed on the Shanghai Stock Exchange's STAR Market (Stock Code: 688105).

Vazyme's product portfolio is extensive, featuring over 200 types of genetically engineered recombinant enzymes, more than 1,000 high-performance antigens and antibodies, and over 500 terminal products. In the life sciences domain, it offers a wide range of molecular biology reagents, including products for PCR, qPCR, cloning, and next-generation sequencing (NGS) library preparation. For the in-vitro diagnostics market, the company provides raw materials and develops diagnostic reagents and equipment for conditions like infectious diseases, cardiovascular diseases, and tumors. Notably, during the COVID-19 pandemic, Vazyme developed and supplied billions of nucleic acid detection raw materials and hundreds of millions of antigen and antibody detection reagents.

Source: Dealroom company data

At a glance

Status
Operational
Founded
2012
Headquarters
China
Open positions
None listed
Dealroom signal
21.3/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotech & Life Sciences, Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
Client focus
B2B
Links
Website

Funding history

8 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
IPOOther financing Dec 2021 $340M $340M Undisclosed —
SERIES COther financing Dec 2020 $76M $303M Sherpa Venture Partners · China Life Private Equity Investment ↗
Showing the latest 2 of 8 recorded eventsBook a demo for the full funding history →

Financials

Revenue, earnings and profit over time

Revenue, earnings and other financial measures where available. Years marked “E” are estimates.

Company filings, research estimates and Dealroom dataBook a demo for the full financial model →

Growth signals

Vazyme Biotech website traffic

Latest recorded traffic for Vazyme Biotech is 32K monthly website visits, up 18.5% over the last three months.

Latest monthly visits32K 3-month web change+18.5%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Vazyme Biotech in its local ecosystem

Live from Dealroom

The Vazyme Biotech office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

8 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed1 investor entered at this stage

  • Danen Capital

Series A3 investors entered at this stage

  • GF Xinde Investment
  • Share Capital
  • Everest Venture Capital

Series B and later3 investors entered at this stage

  • China Life Insurance
  • Sherpa Venture Partners
  • China Life Private Equity Investment

Other known investors1 additional known investor

  • Nanjing University
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇨🇳 China HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Vazyme Biotech on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Vazyme Biotech’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.